Your Current Position: NEWS
-
【Industry Trends】 J Clin Invest 128(4): The mechanism of tumor resistance to oncolytic viruses discovered2018-06-07An article entitled "PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy" published online in the J Clin Invest indicates that PD-L1
-
2018-05-15In Nature, a news titled “Cancer killing viruses show promise – and draw billion-dollar investment” mentioned, pharmaceutical giant Johnson & Johnson announced on 2
-
【Company News】 Converd’s clinical trial of using oncolytic virus in combination with immunotherapy for gastrointestinal cancers2018-04-30Converd has initiated a phase I/II clinical trial: A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer agent (A01) with Immune Cells (IC01) in patients with Advanced Gastrointestinal Cancer.
-
【Company News】 A clinical study of CAR-NK for treatment of metastatic solid tumors is conducted by Converd’s subsidiary, Hangzhou Youshan Sictech Ltd.2018-04-30This clinical study has started in the in the 3rd hospital of Guangzhou Medical University. It is designed to evaluate safety and efficacy of a novel CAR-NK cell therapy for patients with an advanced cancer.
-
On Feb. 22, 2018, Merck and Viralytics announced acquisition agreement and the proposed acquisition values the total issued shares in Viralytics at approximately AUD 502 million (USD 394 million).
-
【Company News】 Deputy Dean Xv Xuehu and Director Sheng Xiujie of the Third Affiliated Hospital of Guangzhou Medical University came to Converd for academic exchange2018-02-22On January 13, 2018, Deputy Dean Xv Xuehu and Director Sheng Xiujie of the Third Affiliated Hospital of Guangzhou Medical University came to our company for academic exchanges.
-
【Company News】 Dean Zhong Zhengxiang and Doctor Bao Yi of Jiaxing 2nd Hospital came to Converd for academic exchange2018-02-22On February 3, 2018, Dr. Zhong Zhengxiang and Dr. Bao Zheng from Jiaxing 2nd Hospital came to our company for academic exchanges.
-
【Industry Trends】 Science Translational Medicine 10 (422): Oncolytic virus immunotherapy breakthrough again2018-02-01In the 10th issue of the 422th issue of Science Translational Medicine, the new results of oncolyticvirus-related immunotherapy were on the cover in the journal Science Translational Medicine 10(422).
-
Converd has completed and moved to its new R & D center in Hangzhou. The Center holds 1,000 m2 area of laboratory space for Molecular and Cellular biology
-
【Industry Trends】 Sep. 7, 2017 Cell: Oncolytic virus and c-Rel inhibitors make immunotherapy more effective2018-01-11Immunotherapy is a promising approach in the treatment of cancer; but for most patients, immunotherapy drugs so far have failed to live up to their promise and provide little or no benefit. Immunotherapy